胃肠道药物市场基于(关键地区、市场参与者、规模和份额)- 到 2031 年的预测

  • Report Code : TIPRE00014758
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 211
Buy Now

[研究报告]胃肠道药物市场规模预计将从2019年的4904,338万美元增长到2027年的71,300.28百万美元;预计 2020 年至 2027 年复合年增长率为 4.9%。

分析师观点

生物制剂开发和新兴领域的投资不断增加预计生物仿制药的销售额将在预测期内以有利可图的速度增长。制药公司正在投资研发,以发现新的和改进的胃肠道药物。这些是改进的胃肠道药物,这些进步导致了创新药物的推出,这些药物具有增强的功效、改善的耐受性和更少的副作用。更新的药物选择为医疗保健提供者提供了更多的治疗选择和更好的患者结果。胃肠道疾病的医疗意识和诊断技术有所提高。这使得诊断更早、更准确,促使医疗保健提供者开出适当的治疗药物。随着患者意识的提高,对缓解症状、提高生活质量的有效药物的需求也越来越大。此外,先进的医疗设施和高昂的医疗保健支出正在推动各个地区胃肠道药物市场的增长。

市场概况

胃肠道药物是一类用于治疗与胃肠系统相关的疾病和病症的药物,胃肠系统包括参与消化、吸收和消除食物和废物的器官。多种因素可能导致胃肠道疾病,包括感染、炎症、胃酸分泌失衡、溃疡和其他结构异常。一些胃肠道疾病涉及运动异常,这会影响食物通过消化道的运动。增强或调节运动的药物(例如促动力剂)可用于治疗胃轻瘫或肠易激综合征(IBS)等疾病。此外,所有年龄段慢性便秘发病率的增加、非处方药销售的增加、泻药需求的增加以及制造商产品供应的增加都有助于胃肠道药物市场的增长。

战略洞察

市场驱动力

增加生物制剂的开发,推动全球胃肠道药物市场增长

增加生物制剂的开发胃肠道疾病的治疗正在推动市场的增长。在过去几年中,称为生物制剂的新疗法被用于治疗炎症性疾病。目前,FDA已批准Humira、Cimzia、Remicade、Simponi、Tysabri和Entyvio生物制剂用于治疗克罗恩病和溃疡性结肠炎。生物制剂彻底改变了 IBD 治疗,它们在治疗这些适应症方面的成功正在推动生物制剂在其他胃肠道疾病中的使用,例如乳糜泻、嗜酸粒细胞性食管炎和自身免疫性肝炎。新药的开发正在推动市场的增长。例如,2019 年 9 月,杨森制药的 STELARA 获得了欧盟委员会的批准。它将用于治疗成人中度至重度活动性溃疡性结肠炎。这是第一个针对 IL-12/IL-23 通路的生物治疗,IL-12/IL-23 通路是 UC 的重要治疗靶点。除此之外,市场参与者的战略举措(例如在未开发市场推出产品)正在进一步推动市场的增长。例如,2020 年 7 月,武田制药公司在印度推出了其重磅生物药物 Vedolizumab,作为其胃肠道产品组合的一部分。维多珠单抗将以 Kynteles 品牌在印度销售。它将用于治疗慢性炎症性肠病,例如溃疡性结肠炎和克罗恩病。发展中国家的胃肠道疾病病例呈上升趋势。例如,印度目前约有 150 万 IBD 患者。这些市场中新生物制剂的推出预计将推动预测期内的市场增长。

此外,随着产品的推出,市场参与者正在开展不同的在其产品组合中添加创新疗法的策略。这进一步推动了胃肠道药物市场的增长。例如,2020年2月,武田药品工业株式会社收购了PvP Biologics, Inc。此次收购在该公司的胃肠道产品组合中增加了研究药物TAK-062 (Kuma062),该药物将用于治疗不受控制的乳糜泻。该公司计划提交第一阶段研究的数据,以便在即将召开的医学大会上展示。在全球范围内,许多人患有乳糜泻,他们通过遵循无麸质饮食来控制症状。对于出现严重症状的人仍然没有治疗方法。通过此次收购,该公司有望在乳糜泻管理领域带来新的疗法。

细分分析

根据应用,胃肠道药物市场分为炎症性溃疡性结肠炎、克罗恩病、肠易激综合征、胃肠炎、乳糜泻等。 2019年,炎症性溃疡性结肠炎细分市场在胃肠道药物市场中占有较大份额。然而,预计肠易激综合症细分市场在预测期内将成为胃肠道药物市场中最高的复合年增长率。溃疡性结肠炎(UC)的日益流行正在推动胃肠道药物市场预测期内胃肠道药物的采用。根据 NCBI 发表的研究,在美国,每 10 万人中有 34 名儿童患有 UC,而成人的患病率为每 10 万人 263 人。此外,该细分市场的增长可归因于治疗这种疾病的药物的容易获得。此外,许多制造商推出了多种针对UC的生物制剂,这进一步推动了胃肠道药物市场的增长。例如,武田制药 (Takeda Pharmaceuticals)、杨森制药 (Janssen Pharmaceuticals) 和辉瑞 (Pfizer) 都是通过其治疗炎症性溃疡性结肠炎的产品在市场上站稳脚跟的顶级公司。

< h3>区域分析

2019年亚太胃肠道药物市场价值为886,844万美元,预计到2027年将达到1361,835万美元;预计在预测期内复合年增长率为 5.6%。亚太胃肠道药物市场分为中国、日本、印度、澳大利亚、韩国和亚太其他地区。 2019年,日本在亚太胃肠道药物市场中占据最大份额。该国胃肠道药物市场的增长主要是由于日本胃肠道疾病的患病率不断上升,这可能会对胃肠道药物产生需求。根据“日本胃肠道疾病趋势”研究,包括日本在内的东亚国家胃癌发病率较高。另据报道,胃食管反流病(GERD)和IBD的发病率不断增加,这将推动胃肠道药物市场的增长。

此外,新产品的推出和推广用于研究目的的资金也推动了美国胃肠道药物市场的增长。例如,2023 年 6 月,安斯泰来制药公司 (Astellas Pharma Inc.) 宣布向日本厚生劳动省 (MHLW) 提交 zolbetuximab 的新药申请,zolbetuximab 是一种针对 Claudin 18.2 (CLDN18.2) 的一流研究性药物单克隆抗体,用于一线治疗局部晚期不可切除或转移性 HER2 阴性胃或胃食管交界处 (GEJ) 腺癌且肿瘤 CLDN18.2 阳性的患者。因此,上述因素预计将推动亚太地区胃肠道药物市场的增长。

主要参与者分析

胃肠道药物市场分析由赛诺菲、葛兰素史克、强生服务公司、博士健康、阿斯利康、武田制药有限公司、艾伯维公司、拜耳公司、Celltrion Healthcare Co., Ltd.和 LEXICON PHARMACEUTICALS 等参与者组成, INC 等公司凭借其提供的多元化产品组合成为排名前两位的参与者。

近期发展

无机和有机策略,例如合并和胃肠道药物市场的公司高度采用收购。下面列出了胃肠道药物市场的一些近期关键市场动态:

  • 2020 年 7 月,Celltrion Healthcare 获得了欧盟委员会 (EC) 的 Remsima(英夫利昔单抗、CT- P13)。它是一种皮下制剂,用于治疗强直性脊柱炎、克罗恩病、溃疡性结肠炎、银屑病关节炎和银屑病成年患者。
  • 2020 年 5 月,赛诺菲成为 Buscopan 等品牌的领先制造商,随着新型食品补充剂 Buscobiota 的推出,肠易激综合症和缓解便秘的 Dulcolax 已进入消化健康市场领域。 Buscobiota 由三种乳酸菌和两种双歧杆菌组成,可作为慢性便秘的预防药物。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is gastrointestinal drugs?

Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits globally. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.

Who are the major players in the gastrointestinal drugs market?

The gastrointestinal drugsmarket majorly consists of the players such as Sanofi, GlaxoSmithKline plc, Johnson and Johnson Services, Inc., Bausch Health, AstraZeneca, Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Celltrion Healthcare Co., Ltd, and LEXICON PHARMACEUTICALS, INC. are among others.

What are the driving factors for the gastrointestinal drugs market across the globe?

The factors that are driving growth of the market are rise in prevalence of gastrointestinal (GI) diseases and increase in development of biologics are expected to boost the growth of the global gastrointestinal drugsmarket.

The List of Companies - Gastrointestinal Drugs Market

  1. Sanofi
  2. GlaxoSmithKline plc
  3. Johnson and Johnson Services, Inc.
  4. Bausch Health
  5. AstraZeneca
  6. Takeda Pharmaceutical Company Limited
  7. AbbVie Inc.
  8. Bayer AG
  9. Celltrion Healthcare Co.,Ltd
  10. LEXICON PHARMACEUTICALS, INC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports